CoChat
Sign Up
Cited by 121Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchCervical Cancer and HPV Research

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in Women: A Multicenter, Double-Blind, Placebo-Controlled Trial

Mertz, Gregory J.·1997·Archives of Internal Medicine
DOI 10.1001/archinte.1997.00440240109016
Open this paper in CoChat — free account

Abstract

Objective: To evaluate the efficacy and safety of oral famciclovir in the suppression of genital herpes. Methods: In this randomized, double-blind, placebo-controlled trial that was performed at 11 university and 9 private ambulatory care referral centers, 375 women who were 18 years of age or older and had a history of 6 or more episodes of genital herpes during 12 of the last 24 months in the absence of suppressive therapy were treated for 4 months with oral famciclovir, 125 mg once daily or twice daily, 250 mg once daily or twice daily, 500 mg once daily, or placebo. The primary outcome measures included the time to first clinically and virologically confirmed recurrences, and safety as measured by clinical laboratory tests and adverse experiences. Results: The median time to first recurrence was 82 days in the placebo group, 114 days in those receiving famciclovir, 125 mg once daily, and more than 120 days in the other treatment groups. When compared with placebo recipients, the time to the first clinical recurrence was significantly prolonged in subjects who received famciclovir, 125 mg twice daily (hazard ratio, 1.8; 95% confidence interval, 1.0-3.0;P=.03), and in those who received famciclovir, 250 mg twice daily (hazard ratio, 3.6; 95% confidence interval, 1.9-6.9;P<.001). Treatment was well tolerated, and there was no evidence of emergence of resistance during or after suppressive famciclovir therapy. Conclusions: Oral famciclovir, 250 mg, given twice daily for 4 months is an effective, well-tolerated treatment for the suppression of genital herpes in women with frequent recurrences, but single daily doses produced less complete suppression of genital herpes. Arch Intern Med. 1997;157:343-349

Overview

Integrity signals

Registry

Crossref · 10.1001/archinte.1997.00440240109016

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Suppressive therapy reduces frequency of genital herpes recurrences by 70%-80% among patients who have frequent recurrences.

    “Suppressive therapy reduces frequency of genital herpes recurrences by 70%–80% among patients who have frequent recurrences (469–472).”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [470]

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Mertz, G. J.
Corresponding author
Mertz, Gregory J.
ORCID
Mertz, Gregory J.
Venue
Archives of Internal Medicine
Publisher
American Medical Association (AMA)
Published
1997-02-10
Volume
157
Issue
3
Pages
343
ISSN
0003-9926 (ISSN-L)
DOI
10.1001/archinte.1997.00440240109016
OpenAlex
W2059870306
Cited by
121
References
29
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 4 · 2021: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 7 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 3
FWCI
8.86
Type
journal article
Language
en
Open access
closed
Locations
Archives of Internal Medicine (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
famciclovir, genital herpes simplex virus, recurrent herpes, suppressive therapy, oral antiviral therapy, women, time to recurrence, dose comparison, drug safety, drug resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review